Online Submissions

Already have a Username/Password for Safety and Risk of Pharmacotherapy?
Go to Login

Need a Username/Password?
Go to Registration

Registration and login are required to submit items online and to check the status of current submissions.

Author Guidelines

I. Submission

II. Manuscript submission and interaction with the journal

III. Article types

IV. Structure of bibliographic data

V. Contents of the main text sections

VI. Text layout and formatting

VII. Tables and figures

VIII. Mathematical formulae, equations, and symbols

IX. References

X. Footnotes

XI. Additional information, ethical and other statements

XII. Recommended resources for manuscript preparation

I. Submission

General provisions

The journal uses the online submission system available at Elpub and accepts manuscripts in Russian or in English that meet the requirements of the Editorial Policies and Author Guidelines.

Manuscripts are published after successful peer review and approval by the Editorial Board (see the Editing and Publishing Process Flowchart). The journal publishes manuscripts on an unpaid basis.   

For more details on the submission process and communication with the editorial staff, please see the corresponding sections below.

Submission of a manuscript to Safety and Risk of Pharmacotherapy implies the following:

• The manuscript has not been published before.
• It is not under consideration for publication elsewhere.
• The submitted materials do not violate any third-party rights or current legislation.
• The authors have read the Scope, Publication Ethics & Malpractice Statement, and Editorial Policies of the journal.
• When drafting the manuscript, the authors adhered to the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals. The authors meet all 4 ICMJE criteria for authorship, including the criteria for making substantial contributions to the work, drafting the manuscript, checking the final version of the manuscript prior to publication, and accepting responsibility for the work as a whole and for each individual element of it, as well as the obligation to respond promptly to editorial enquiries before and after publication.
• Each author checked the spelling of their name in Russian and English (its correspondence with ORCID), their affiliation, the correctness of the ORCID number, as well as the up-to-date status of its completion.
• The authors have appointed a corresponding author, to whom they delegate the primary responsibility for communication with the journal.

II. Manuscript submission and interaction with the journal

To submit a manuscript, the authors need to register on the journal’s website (https://www.risksafety.ru), fill out the online form, and upload the article, scanned copy of the referral from the institution (cover letter), scanned copy (as one file) of the ICMJE forms on potential conflicts of interest completed by all the authors, and additional documents and supplements to the manuscript (e.g. illustrations, original research data and algorithms, proof of permission to publish borrowed figures if required, etc.).

Only original cover letters should be mailed to the Editorial Board at 8/2 Petrovsky Blvd, Moscow 127051, Russia (127051, Москва, Петровский б-р, д. 8, стр. 2), attn: O.F. Fedotova, Managing Editor.

The journal does not require copies of

• ethics committee decisions,
• patient consents for publication,
• permissions to mention contributors in the Acknowledgements section.

Communication between the journal and the author

The editorial staff communicate with the authors via the corresponding author they have selected. The process a manuscript goes through in the electronic editorial office is presented in the Editorial and Publishing Process flowchart.

All submitted manuscripts undergo preliminary evaluation for compliance with the Author Guidelines (including the requirements for passing a plagiarism check). If a manuscript does not fulfil the requirements, it may be returned to the authors for correction. At this stage, a manuscript may also be rejected if it is not in line with the aims and scope of the journal or lacks originality. The decision on rejection of a manuscript is made by the executive secretary of the journal.  

After checking for compliance, the editors send the manuscript for peer review. The peer-review period takes 1–6 months. In disputable cases, the editorial staff may ask several additional experts to review the manuscript. Copies of the reviews are sent to the authors for their information. Having received two positive reviews, the manuscript is sent to its editor who will prepare it for publication. If the reviewers and/or editors raise any issues, the authors have to make all the necessary corrections within 14 days. If the authors fail to submit the corrected manuscript within this period, the publication date will be postponed. If the authors do not submit the corrected version within 1 month, the editorial staff have the right to withdraw the article from publication, of which the authors will be duly notified. In this case, the authors may submit the manuscript to the journal again, and it will again undergo the full procedure of preparation for publication. The final decision on publication of the manuscript or on its rejection is made by the Editorial Board. 

If the manuscript is accepted for publication, the authors will be sent the final version of the article for approval. The authors have to reply within 2 days. If the authors do not reply, the article is considered approved.

You may find information on manuscript rejection rates and the average turnaround from submission to publication in the Main Info about Journal section.

Revision of the editors’/reviewers’ decisions

If the authors do not agree with the conclusions or some remarks of the reviewers and/or the editorial staff, the authors may challenge the decisions. To do this, the authors will have to provide written arguments for each remark and send a letter to the editorial staff.

The journal encourages resubmission of manuscripts that are potentially acceptable but were rejected because major revisions or additional data were required. The editorial staff will provide a detailed explanation of what should be corrected for the manuscript to be accepted for publication.

Actions taken by the editorial staff upon discovery of plagiarism, data manipulation, or falsification

In case the editorial staff discover any research misconduct on the part of the authors, including plagiarism and data manipulation or falsification, the journal adheres to the principles of COPE.

Safety and Risk of Pharmacotherapy understands “misconduct” as any actions of researchers, including mistreatment of test objects, or intentional manipulation of research data so that these data no longer reflect the observations, as well as any actions of the researchers that do not comply with ethical and scientific norms.

Safety and Risk of Pharmacotherapy does not regard the following as research misconduct: honest mistakes; unintentional discrepancies in the planning, conduction, interpretation, or assessment of research methods or results; or misconduct not affecting the research.

If plagiarism, data manipulation, or falsification are discovered at any stage of article preparation, the Editorial Board will consider rejection of the manuscript.

Correction of mistakes and article retraction after publication

If an article is found to contain mistakes that affect perception but do not confound the research results, these mistakes may be corrected by replacing the pdf version of the article (with a statement about the mistakes in the pdf file and on the journal’s web page). If there are mistakes that confound the research results or plagiarism/research misconduct related to data manipulation or falsification, the article may be retracted. The retraction may be initiated by the journal, an author, an organisation, or a private individual. The retracted article is labelled RETRACTED, and the reason for retraction is stated on the article’s page. Indexing databases are notified of retraction. For more information on the peer review process, possible author changes, ethical oversight, complaints, appeals, and post-publication corrections, please see the relevant sections on the journal’s Policies page.

III. Article types 

Clinical practice guidelines

Systematic reviews and meta-analyses

Narrative reviews

Reviews to evaluate the benefits, risks, safety, and efficacy of a medicinal product

Original research / papers

Brief communications

Surveys

Controlled clinical trials

Case reports and case series

Interviews

Editorials

Commentaries to published articles and responses to commentaries

Clinical practice guidelines

Volume: up to 9,000 words (all sections of the file)

Generally, clinical practice guidelines are a result of the journal’s close cooperation with national and international professional associations. The guidelines published in the journal are subject to evaluation using the Appraisal of Guidelines for Research & Evaluation (AGREE) II tool or the Delphi approach.

Since often the format of the original national guidelines differs from that of international guidelines (for example, Russian guidelines do not have an abstract), the journal together with the guideline authors make every effort to create an abstract in English, maximally adapted to the AGREE and RIGHT requirements, for better indexing and visibility in international databases.

Suggested guidelines:

• The AGREE Reporting Checklist: a tool to improve reporting of clinical practice guidelines
• A Reporting Tool for Practice Guidelines in Health Care: the RIGHT Statement
• Reporting Items for Updated Clinical Guidelines: Checklist for the Reporting of Updated Guidelines (CheckUp)

Systematic reviews and meta-analyses

Volume: up to 9,000 words (all sections of the file)

This type of publication is a systematic critical analysis of literature and data sources on a clinical topic, with a focus on causes, diagnosis, prognosis, therapy or prevention of a condition, and further generation of data to address the research question or hypothesis posed. All literature or data sources should undergo systematic selection and screening for inclusion and critical appraisal. The search and selection process should be described in the Materials and Methods section. The authors of a meta-analysis should describe the specific type of study or analysis, population, intervention, exposure, tests, and results for each publication or data source to ensure that the materials analysed are homogeneous. Data sources should be as current as possible. Ideally, the search should take place within a few months prior to manuscript submission.

For meta-analyses of randomised controlled studies, the authors are required to provide the PRISMA flowchart and checklist.

For meta-analyses of observational studies, the authors are required to provide the MOOSE flowchart and checklist.

Suggested guidelines:

• The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
• MOOSE (Meta-analyses Of Observational Studies in Epidemiology) checklist

Narrative reviews

Volume: up to 6,000 words (all sections of the file)

Generally, narrative reviews are solicited by the journal. Narrative reviews are systematic analyses of the current literature, most often with the aim of bringing forth a new classification or substantiating controversial and/or innovative hypotheses. Although this type of publication assumes free organisation of the main part, the journal requires it to be clearly structured and to have a system of subheadings. Reviews written in continuous text will not be accepted.

The journal establishes the following 3 mandatory sections for a review article:

1. Introduction: a brief overview of the topic (background information on what is known, possible, controversial), a rationale for the review (its importance, novelty, necessity), a plausible hypothesis to be proved, and the search strategy (databases, keywords and search period covered).
2. Main part: analysis and discussion of literature. This part must have a structure and subheadings; continuous text will not be accepted.
3. Conclusion: main conclusions, potential limitations, clinical significance, directions for future research.

Since this type of publication requires analyse and syntesis of up-to-date data, rather than paraphrasing the known information, the authors are advised to visualise their work as much as possible through tables and figures. If reused, graphical materials should be properly referenced. If taken from sources distributed under a licence other than CC BY, graphical materials should be accompanied by a notice "used with permission of the copyright holder".

A narrative review may contain up to 6,000 words. A structured abstract is required (with a minimum of 3 sections as recommended above). The title should include an indication of the type of article at the end (please state that the article is a review after a colon). The authors may use up to 5 tables or figures. The references should list at least 40–60 publications issued within the last 3 years.

For quality assessment of narrative review articles we recommend to use SANRA scale.

Suggested materials:

• Review template

Reviews to evaluate the benefits, risks, safety, and efficacy of a medicinal product

Volume: up to 6,000 words (all sections of the file)

This type of review aims to provide an independent assessment of the safety of a particular medicinal product and the best practices for its use. The title should sound objective and unbiased (no advertising), and the product should be referred to by its INN (International Non-proprietary Name). The abstract should be structured according to the logic of material presentation set by the author in the full text.

The following structure is recommended for the full text:

1. Introduction:

• Justification of the importance of the topic (e.g. information on the incidence and prevalence of a disease, the unmet medical needs, and the existing treatment guidelines (with an emphasis on regional differences, when appropriate));
• Background to the development and use of the medicinal product described.

2. Main part:

• Description of the mechanism of action, including pharmacokinetics and pharmacodynamics data;
• Information on the clinical use, including efficacy data.

3. Safety assessment (this section should form the main part of the review):

• Safety in clinical trials;
• Post-marketing data;
• Safety in special populations (including pharmacogenomics data, if available).

4. Comparisons with other medicinal products:

• Tabular data comparison, if appropriate.

5. Conclusion:

• Analysis and interpretation of the data presented in the review;
• Up to 3,000 words and up to 100 references.

Original research / papers

Volume: up to 6,000 words (all sections of the file)

These are designed to present original unpublished research findings that contribute novelty to clinical or experimental practice and that can be subsequently replicated and generalised (based on the study design specified in the manuscript and detailed description of methods). Original studies have many types and formats depending on their aim, design, and other characteristics. For example, they include brief communications, prospective and interventional studies, surveys, and randomised controlled trials. For the convenience of the authors, original research papers are categorised according to international guidelines, established practice, and the journal scope.

The formal structure of the full text and abstract of an original research paper should correspond to the chosen research design (EQUATOR Network guidelines). The most common structure is the IMRAD style, including Introduction, Aim, Materials and Methods, Results, and Discussion sections (a Conclusions section is acceptable). The editorial staff recommend using subheadings, especially in the Discussion section (where the authors should outline the novelty, clinical significance, limitations of their study, recommendations for follow-up research, and most importantly, if possible, the place of their study in the context of existing studies). This type of publication should clearly state the research question in the Aim section.

For interventional studies, the Materials and Methods section should be as detailed as possible in accordance with the TIDieR-Checklist and the relevant guidelines.

For diagnostic/prognostic studies (prospective studies designed to develop, validate, or update the diagnostic or prognostic accuracy of a test or model), the STARD and TRIPOD guidelines should be used.

For randomised controlled trials, the appropriate CONSORT checklist and its variants/supplements should be used (see the Clinical Trials section below).

For experimental in vivo studies, the authors should consider the layout and the coverage of issues set forth in the ARRIVE guideline. A detailed explanation and relevant checklists can be found at the ARRIVE resource portal.

For all clinical and experimental studies involving only one gender, the authors should reflect this in the title of the manuscript and the Discussion section, according to the SAGER guidelines.

For Observational Studies in Epidemiology (STROBE) please use relevant checklist available at EQUATOR Network. 

Suggested materials:

• Original article template

Brief communications

Volume: up to 2,000 words (all sections of the file)

This type of publication represents a brief report that may include:

• preliminary study data with anticipated findings that warrant a more definitive study;
• replication studies based on known protocols that partially complement previously published studies;
• studies on important topics that report negative results.

These articles should not exceed 2,000 words and may have an unstructured abstract, structured text, 1 or 2 tables, 1 or 2 figures, and references to sources.

When designing, conducting, and writing a "feasibility assessment of...", which is the most common topic for brief communications, the authors should use the How We Design Feasibility Studies guideline, which discusses 8 feasibility criteria and often adds a 9^th criterion, safety.

Surveys

Volume: up to 6,000 words (all sections of the file)

Manuscripts reporting survey data, such as studies involving patients, clinicians, the public, or others, should report data collected as recently as possible, ideally within the past 2 years. Survey studies should have sufficient response rates (generally, at least 60%) and appropriate characterisation of non-responders to ensure that non-response bias does not threaten the validity of the findings. For most surveys, such as those conducted by telephone, personal interviews, mail, e-mail, or online, the authors are encouraged to report survey outcome rates by using standard definitions and metrics, such as those proposed by the American Association for Public Opinion Research. In addition, the authors should submit the survey instrument, if possible, as a separate file, which may be considered for publication online as a supplement to the article. Posting raw data and algorithms in public repositories is also encouraged.

Suggested guidelines and materials:

• Standard Definitions by the American Association for Public Opinion Research (AAPOR)
• A Guide for the Design and Conduct of Self-Administered Surveys of Clinicians
• Good Practice in the Conduct and Reporting of Survey Research
• Checklist for Reporting Results of Internet E-Surveys (CHERRIES)

Controlled clinical trials

Volume: up to 6,000 words (all sections of the file)

This type of publication is designed to present clinical trials with a control group. These articles should not exceed 4,500 words. The text layout should include Introduction, Aim, Materials and Methods, Results, Discussion, and Conclusions. It is recommended to use subheadings, especially in the Discussion section. The clinical significance and limitations of the study should be clearly stated in the Discussion section. The topical material and methods should be carefully detailed.

This type of publication requires a structured abstract, including Introduction, Aims, Materials and Methods, Results, Discussion, and Conclusions.

For randomised clinical trials, the editorial staff recommend pre-registering the study protocol (e.g. on clinicaltrials.gov) and posting the raw data in public repositories.

Suggested guidelines:

• SPIRIT 2013 Statement: Defining standard protocol items for clinical trials
• CONSORT 2025 Statement: updated guidelines for reporting parallel group randomised trials 
• Updates to CONSORT reporting guidelines 

Case reports and case series

Volume: up to 4,500 words (all sections of the file)

This type of publication should describe the development of unreported or rare adverse drug reactions (which should be substantiated by an appropriate literature search and analysis and reflected in the Introduction and Discussion sections). The journal does not accept clinical cases in lecture format demonstrating known medical interventions and outcomes.

Essential elements of this publication are:

• A rigorous review of literature to substantiate the adverse drug reaction observed for the first time or described in similar publications for subsequent discussion;
• A detailed picture of the patient’s follow-up from admission to discharge supplemented with some form of visualisation (e.g. figures and tables);
• A section (statement) on obtaining consent for publication from the patient (or their legal representatives). If it is not possible to identify the patient from the described medical history and submitted photographs and, thus, the patient’s consent is not required, please add a statement to that effect.

The journal does not require the authors to provide a copy of the completed consent form, nor does it require this consent form to meet any standards. However, for the convenience of the authors, the journal provides a list of items commonly found in such consent forms.

A case report should not exceed 3,500 words. The expected scope of literature is at least 15–30 sources.

Suggested guidelines and materials:

• The CARE Guidelines: Consensus-based Clinical Case Reporting Guideline Development

• Case report template

Interviews

The editors of the journal conduct interviews with leading experts in pharmacy, medicine, and public health on current issues, promising research, and innovations. The interviews can be conducted in person, by e-mail, or by telephone. This type of publication requires a photograph of the interviewee (high quality, preferably business style). The journal does not allow promoting unpublished interviewee’s manuscripts. For better perception and visualisation of the interview text, the journal expects the interviewee to recommend some literary sources or authors prior to the interview and to highlight key issues or conclusions after the interview. These recommendations and highlights will be displayed in the form of special inserts (figures, bullet list, etc.) in the published interview. The final text of the interview is always agreed with the interviewee before publication.

Editorials

Editorials are short publications on topical issues written by leading experts in a given subject area, upon request from the Editorial Board. The main aim of this type of article is to express the author’s opinion and personal view on a current topic (e.g. development and use of innovative medicines or discussion of various therapeutic strategies that are currently being studied and may deepen the readers’ professional knowledge).

The maximum length of editorials is 1,000–1,500 words.

There should be no brand names of medicinal products in the title. No abstract is required. An editorial should include a small introduction with background information on the field under consideration. Preferably, the main part should contain a numbered list of the issues addressed. These may include the following:

• What are the main directions and prospects for research in this field at this time?
• What is the potential and ultimate goal of this research? What is needed to achieve this goal?
• How do the authors see the development of the field in the coming years?

The authors of this type of publication may refer to a maximum of 15 literature sources. References to unpublished data should be minimised, and the authors should obtain written consent from the cited individuals to use unpublished results or personal communications in the manuscript. The journal encourages highlighting the top references in the authors' opinion.

The authors of this type of publication may include 2 tables and 2 figures.

Commentaries on published articles and responses to commentaries

Commentaries are provided as reasoned feedback that addresses scientific, methodological, ethical, or clinical aspects of the materials published in the journal, as well as their interpretation. Commentaries are accepted no later than 2 months from the date of article publication. When making a decision on publication, preference is given to commentaries on articles labelled "Editors’ Choice". If possible, commentaries accepted by the Editorial Board are published together with the response of the authors of the original article to this commentary. As an exception, a commentary and a response to it may be published in the issue after the next. Only one round of commenting and responding is allowed, without continuing the discussion in subsequent issues of the journal. Commentaries and responses are required to include the References section, including 2–10 items, where the commented article or commentary should be cited, as well as sources supporting the arguments of the opponent.

Title guidelines:

• A commentary title should include the original title of the commented article in quotation marks, preceded by the phrase and a colon "Commentary on the article:…", and followed by the first author of the original article.
• A response title should include the title of the commentary with the addition of "Response to commentary:…" at the beginning.

IV. Structure of bibliographic data

Bibliographic data of an article (including the title of the article, names and ORCID profiles of its authors, the abstract, etc.) are metadata used for correct indexing of the article in Russian and international databases, library collections. Bibliographic data are also used for DOI generation. Therefore, these data should also be provided in English.

Correct indexing, potential visibility, and citability of an article depend on the correctness and completeness of the bibliographic data presented by its authors. For example, if an author spells their name differently from the variant used in their ORCID profile, the publication will not show in their record automatically. If authors do not mention a standard study design in the title or abstract, their paper might not be included in a systematic review that only considers studies of a particular design. Databases will not be able to index an article correctly and completely if its abstract does not specify the international non-proprietary names of the studied medicinal products; the administration methods used; the pathological condition of interest; or the sex, age, and other patient characteristics. This will reduce the chances of finding the article for potential readers.

Bibliographic data organisation in the order they appear in the manuscript

UDC (Universal Decimal Classification). It is provided in upper left-hand corner of the first page of the manuscript. The authors should select the UDC code based on the subject of the article.

Manuscript title. The title should correspond to the content of the article, be informative, and fully reflect the main aim set by the author for covering the topic. The title should not include hollow and meaningless science-like words (e.g. about the issue of studying…). The title should not contain acronyms or abbreviations except for those listed in the MeSH (Medical Subject Headings).

Standard study designs should be specified at the end of the title after a colon (e.g. “randomised controlled study”, “systematic review”, “case report”).

The title of a manuscript should not exceed 13 words.

Author initials and last names. The authors should submit their full name in English according to their ORCID profile (published name). When filling in their published name in the ORCID profile in the first place, the authors should use the spelling they have used the most in their previous publications. Full names in English should be laid out as follows: the first name, the initial of the patronymic, and the last name (Ivan I. Ivanov). The order of authors’ names in their publications is decided upon by the authors. The corresponding author, who is responsible for all correspondence of the authors with the editorial staff, and subsequently the readers, should be indicated with an envelope symbol in superscript to the right of their last name.

Author affiliations. An affiliation of an author should specify the full official name of the organisation (according to the Charter) and its postal address (street, house number, city, zip code, and country). The journal allows multiple affiliations; please indicate all places of employment relevant to the research. If the authors of a manuscript are from different institutions, the affiliations of each author to a particular institution should be indicated in superscript. For correct indexing in international citation databases, please do not include quotation marks or the form of incorporation and departmental affiliation.

ORCID profiles. The Editorial Board of the journal recommends each author to use and annually update their ORCID profile. An ORCID profile helps with correct indexing of the author in databases (one click to a complete and up-to-date report on their scientometric indicators), automatic addition of publications (without manual entry) to the author’s ORCID profile (as well as other profiles), and providing readers with comprehensive information about the author and the author’s expertise. Therefore, a minimally completed ORCID profile is required from the corresponding author. 

Corresponding author. As stated above, this person’s name should be repeated in the footnote, including the full name and an e-mail (preferably corporate, as another e-mail may be considered as an indicator of a potentially fake article).

Abstract. The abstract should be 150–300 words. It should describe the content of the manuscript as detailed as possible. Abstracts of original papers, reviews, and brief communications should be structured according to the type of article, as described above. Generally, a brief description of the importance of studying the topic should be followed by separate subsections succinctly summarising the aim of the work, materials and methods, results, discussion, and conclusions. The subheadings of these sections should be marked in bold (see article templates: review, original paper, and case report). The abstract should not include any references. The editorial staff recommend against using abbreviations and acronyms (except those contained in the MeSH thesaurus). If a registered study protocol is available (especially, for randomised controlled trials) it should be mentioned at the end of the abstract under the heading REGISTRATION as follows:

• REGISTRATION: Clinicaltrials.gov identifier: NCT03945968. Registered: 10 May 2019.

Keywords are the most significant words or word combinations on the topic of research, reflecting the specifics of the topic, study objects, and results. Key words are used to search for articles in databases. The list of keywords should include 5–9 words or word combinations that complement the summary and title of the article. There should be no more than 3 words in one word combination. Words in a word combination should not be separated by a comma. Quotation marks should not be used. Keywords should be given in the nominative case and separated by a semicolon. There should be no full stop after the keywords. For selecting keywords in English, the editorial staff recommend using the MeSH thesaurus of medical terms.

Bibliographic data for citation. Please use the following template.

• Petrov V.I., Ryazanova A.Yu., Tokareva N.S. Analysis of the consumption of medicinal products associated with a high risk of drug-induced liver injury in patients with COVID-19. Safety and Risk of Pharmacotherapy. 2024.

Upon acceptance for publication, the editorial staff will supplement these data with relevant details.

V. Contents of the main text sections

As stated above for the basic types of articles, the layout of the main text sections may vary considerably depending on the study design and the applicable EQUATOR Network guidelines. However, these sections generally retain the same logic of presentation: introduction, aim, materials and methods, results, discussion, and conclusions.

The authors should emphasise the following in these sections.

Introduction

• The section should include a brief assessment of the current state of research on the topic.
• The section should explain the novelty, importance, and aim of the study.

Aim

• The section should answer what the purpose of the research is. It should explain the research question or the hypothesis being proved (if the aim of the study is to prove a hypothesis).
• If the study tested the null hypothesis, this should be stated.
• The aim should be consistent with the title and the conclusions.
• This section may also list additional objectives.

Materials and methods

• This section is required for original articles.
• It should describe the materials, study objects, and methods in sufficient detail to allow for reproduction of the study.
• The choice of experimental objects should be justified. The Materials and Methods section should specify the number of participants and the methods of their selection (inclusion/exclusion criteria).
• The section should specify the number of patients who withdrew from the study due to side effects.
• Information on the sources of all animals, cell cultures, strains of microorganisms, etc. used in the work should be specified accurately and in detail. The Materials and Methods section should specify the purity qualification and manufacturer of the reagents used, as well as the brand and manufacturer of the instruments and equipment used in experiments.
• Company names should be given in their original spelling.
• Where possible, the international non-proprietary names of medicinal products should be given instead of their trade names. Articles on clinical trials should be provided with information on ethics committee approval (with the name and number of the approval document).
• Studies involving human subjects should include an indication of compliance with the 2024 Declaration of Helsinki.
• Research involving animals should include an indication of compliance with international, national, or institutional animal welfare regulations.
• It should be made clear what types of consent were obtained (e.g. for participation in the study, for publication of anonymised data).
• The conditions and sequence of operations used in the experiments and the software used in the study should be specified.
• It is not necessary to describe known methods in detail; a relevant reference will suffice.
• This section should detail the randomisation process.
• The methods used for blinding and statistical processing of results should be specified.
• If an AI-based software was used for drafting the manuscript, the name and version of the software should be given, as well as the prompts. Example: While preparing this study, the author(s) used [TOOL/SERVICE NAME] in order to [THE REASON]. After using this tool/service, the author(s) have reviewed and edited the content as needed and assume full responsibility for the publication content.

Results

• The results should be presented in the same order as the methods are described.
• This section should outline key outcomes and outcome indicators.
• Baseline and endline data for the sample should be provided in this section.
• This section should specify absolute values (e.g. increases, decreases, or absolute differences between groups), effect sizes, and appropriate measures of uncertainty, such as confidence intervals (CIs).
• This section should include mean values and standard deviations for normally distributed data, as well as medians and ranges or interquartile ranges (IQRs) for data that are not normally distributed.
• Statements solely about the results of statistical hypothesis testing, such as P-values, that cannot convey important quantitative information, should be avoided.
• In most studies, P-values should follow reports of comparisons of absolute values or measures of uncertainty (e.g. 0.8%, 95% CI: -0.2 to 1.8%; P=0.13).
• P-values should not be presented in isolation, without the data being compared. Approaches such as the calculation of the number of treatments per unit of benefit may be mentioned, if appropriate. Relative risk measures (e.g. relative risk, risk ratios) may also be reported and should include CIs.
• Studies of screening and diagnostic tests should report the sensitivity, specificity, and likelihood ratios observed.
• If a prognostic value or accuracy is reported, the prevalence or pre-test probability should also be reported.
• All randomised clinical trials should include results obtained from analyses of treatment assignment and side effects.
• All descriptions of surveys should include response rates.
• No personally identifiable information (patient names and initials, medical record numbers) may be published. Photographs submitted for publication should not provide for patient identification.
• The journal welcomes pre-posting of all raw research data in public repositories that assign DOIs (e.g. Mendeley Data).

Discussion

• This section should provide a critical and objective examination of the research undertaken or an interpretation of the results (i.e. discussion of the results in comparison with other publications on the topic).
• The section should consider the research question or the study hypothesis (also from the perspective of comparison with other studies).
• It should discuss the results, rather than repeat them.
• The novelty, limitations of the study, and potential biases unaccounted for in the study should be described and recommendations should be given for future research.

Conclusion(s)

• This section should include only conclusions directly supported by the results.
• Equal emphasis should be put on positive and negative findings of equal scientific value.
• The importance and clinical relevance of the study should be described without speculation or overgeneralisation.
• This section should state, if necessary, whether additional research is required to begin using the obtained information in a clinical setting.
• This section may present the findings as a numbered list. In this case, it should be called Conclusions.

VI. Text layout and formatting

Formatting

• margins: upper and lower: 2 cm, left: 3 cm, right: 1.5 cm.
• type: 14-point Times New Roman with 1.5-line spacing (main text); 12-point Times New Roman with 1-line spacing (abstract, keywords, data for citation, corresponding author data, tables, figure captions, acknowledgements, disclosure statement, reference list, and information about the authors)

 Abbreviations and glossaries

• Abbreviations are allowed in the manuscript if written out in full at the first mention.
• Abbreviations given in the abstract should be defined once again in the body text.
• Common abbreviations (e.g. DNA, COVID-19) do not need explanation at first mention.
• The manuscript may be provided with a glossary of terms and abbreviations, which should be placed at the beginning before the Introduction section.

Units of measurement

Units of measurement and other numerical values should be given according to the SI system.

 Citations

• Citations should be verified and properly formatted.
• References to literature sources in the text should be numbered in square brackets.
• Non-indexed sources (see the Literature section) should be referenced in footnotes.
• References in the body text including names should start with initials before last names (According to P.M. Ivanov et al. [25], as well as J.K. Johnson et al. [26]).
• Foreign last names should be spelled as in the source publication.
• When citing preprints, the authors of the manuscript should note "preprint" in parentheses in the most appropriate place in their opinion (according to P.M. Ivanov et al. [25] (preprint)).

Full stops

• Do not put a full stop after the title of the manuscript; subheadings; keywords; links; titles, notes, and captions of tables and figures; measurement units (e.g. с, секунда; г, грамм; мин, minute; сут, day; град, degree), some numerals (млн, million; млрд, milliard; трлн, trillion), subscripts (Т_пл, melting point; T_ф.п, phase transition point).
• Put full stop after truncations (мес., month; г., year).

Latin

• Latin names of research objects should be written in compliance with generally accepted taxonomy nomenclature; binomial names of species and higher taxa are usually typeset in italics (e.g. Valeriana officinalis, genus Valeriana, family Valerianaceae).
• Genus and species names should be given in full at the first mention in the text; thereafter, the generic name may be indicated by one (first) capital letter, and the species name should be indicated in full (e.g. officinalis L.).

Names and symbols

• Names and symbols of genes should be in italics, and names of gene products should be in regular font and start with a capital letter, e.g. genes: fos, c-myc, ATM; proteins: Fos, c-Myc, ATM.
• Names of mobile genetic elements and the first three letters of restriction sites should be in italics, e.g. hobo-element, Hin
• Names of phages and viruses should be in Latin in regular font.

VII. Tables and figures

All tables and pictures included in the manuscript should be should be mentioned in the text and appear in order of mention. Tabulated data and figure captions should not repeat the same information.

Tables

• Tables should include editable text and should be created in Microsoft Office applications. Each table should have a title that includes its number and name, e.g. “Table 2. Description of vital processes”.
• There should be no full stop at the end of the table’s heading.
• Russian text in tables should be provided with translation into English.
• Translated title should be placed below the title in Russian.
• Headings are aligned to the left. Tables are numbered using Arabic numerals in order of appearance in the text. If there is only one table in the text, it should still be numbered.
• References to the tables are made as follows: “Table 3 ..” («В таблице 3 указано, что …») or “It is indicated... (Table 3)” («Указано, что … (табл. 3)»). Headings of columns and rows should be highlighted in bold.
• There should not be any empty cells in tables. If the authors have no data to put in a cell or there are other reasons for a cell to be empty, the authors should make a note to that effect in this cell or in the note to the table.
• It is not recommended to use abbreviations in tables, but if they are necessary, their interpretation should be given in the note to the table.
• All data presented in tables should correspond to those in the text of the article.

Figures

• Each figure should have a caption that includes its number and title, for example: “Fig. 2. Description of vital processes”.
• There should be no full stop at the end of a caption.
• Figures should be numbered using Arabic numerals in order of their appearance in the text. If there is only one picture in the text, it should still be numbered.
• Figures should be referenced in the text as follows: “Figure 3..” or “It is shown... (Fig. 3)”. Graphs and photographs should have a clear legend (descriptive text) that explains the meaning of the figure without the need to read the full text of the manuscript.
• The authors should use vector formats (svg, al, eps, cdr) but may use raster formats (jpg, tif), as well as pdf.
• All graphs and figures should be designed to be fully accessible to colour-blind readers (e.g. by introducing different numbers/letters/symbols for curves or areas presented in different colours). Generally satisfactory manuscripts having a non-accessible design will be returned to the authors for modification in line with this accessibility recommendation.
• All illustrations should be either in RGB (colour) or grayscale (black and white) mode.
• Any graphs and charts (with numerical data) should be made using Microsoft Excel 2003 and later and placed in linked documents or provided as separate files in XLS or XLSX formats (with places where the figures should appear marked in the manuscript).
• In the case of using third-party spreadsheet processors and specialised plotting and charting software, the authors should provide either a screen copy or a copy for a virtual printer in pdf (preset to Press Quality) or other vector format.
• Raster figures (e.g. photographs, scans, and screenshots) should be submitted not only as part of the text but also as separate files with a resolution of at least 300 dots per inch, and in JPEG (without compression), TIFF, or PNG format.
• Each figure should be submitted as a separate file with a name reflecting the number of the figure as it appears in the text (e.g. a file with Fig.1.21 may be named 1–21.tif).
• If illustrations are created using some software, the original file in the format for the software should be attached (e.g. xls for Excel, cdx for Corel Draw, etc.).
• The authors are advised to evaluate the feasibility of using a pie chart (or replacing it with a line chart, as it would illustrate the values more clearly) before submitting the manuscript.
• The journal discourages the authors from using coloured backgrounds in graphs.
• The authors should not use shadows in line graphs, nor 3D graphics inappropriate for two-dimensional figures.
• Micrographs should have internal scale markers.

In the case of reused figures, it is necessary to ensure the correct attribution of reused figures (either in the body of the manuscript or in the figure caption). If a borrowed figure is distributed under a licence other than CC BY, which implies the use of content without permission of the copyright holder, the authors of the manuscript should request permission from the corresponding author of the original publication with the figure and attest that appropriate permission has been obtained in the caption to the borrowed figure. 

VIII. Mathematical formulae, equations, and symbols

Stand-alone mathematical formulae (placed on a separate line) should be generated as a single MathType element. Formula formatting as sets of different elements, such as a table, a text, or a filled-in box, is unacceptable. The article should not contain any formulae formatted as images.

MathType equations should use the software’s default settings for font type, size, and placement of symbols:

• Digits should be in regular font.
• Latin letters (alphabetical symbols) denoting values should be in italics.
• Abbreviated mathematical symbols (e.g. sin, cos, lg, lim, max) should be in regular font.
• Russian letters (both in formulae and subscripts/superscripts) should be in regular font.
• Subscripts/superscripts should be in regular font—e.g. N_fin (i.e. N_final), C_max, S_mean—with no full stop at the end.
• Greek letters should be in straight font.
• Symbols of chemical elements should be in regular font.

Simple mathematical and chemical formulae (e.g. a₂ + b₂ = c₂; H₂SO₄) and individual variables or symbols should be presented as simple text and should not be included in filled-in boxes (MathType is not needed). If an equation is too long to fit into one line, it should be carried forward to the next line after an equal sign (=), a plus sign (+), a minus sign (‒), a multiplication sign (×), or another mathematical sign, provided that the sign is repeated at the beginning of the new line.

Numeric symbols and numerical factors should be explained immediately below the formula/equation in order of appearance. Formulae and equations are assigned sequential numbers that run through the whole text of the manuscript. The authors should use Arabic numerals in brackets for numbering formulae and place each number at the right end of the corresponding line. For example:

A single formula/equation should be denoted as (1). In-text references to formula/equation numbers should be provided in Arabic numerals in brackets. In English, decimal places in digits are separated with a full stop, and not with a comma (0.25 instead of 0,25). The reverse is true for Russian text (0,25 instead of 0.25).

IX. References

The authors are responsible for the accuracy and completeness of the data they provide in the list of references.
The reference list should include only indexed national and international sources—articles from scientific journals and collections (including online ones), monographs, patents— preferably, published over the last 5–7 years.
Other documents and regulatory documents, including pharmacopoeial articles) should be cited in footnotes (see the Footnotes section).
The journal adheres to an adapted version of the Vancouver style, rather than the Russian GOST, which is informational in nature.
International citation systems require that the References section should be included in the English-language part of the article. Accordingly, references to sources should be made not only in the original language but also in the Latin (Roman) alphabet, according to official translations (not by free transliteration). If a source does not provide a ready-made citation for reference lists, it is acceptable to transliterate the title of this source and its authors' names. In this case, the BSI format should be used.
The use of hyphenation for word breaks (especially DOIs) is prohibited, as this may impede correct indexing in databases.

Other recommendations:

• References should be numbered consecutively in the order they are first used in the text.
• The number of references in the list depends on the type of publication. However, the journal encourages including ≤60 references per manuscript. References to articles that have been accepted for publication but have not been published yet should state “in print” in square brackets. The authors should obtain written confirmation that such articles have been indeed accepted for publication. References to preprints should state “preprint” in square brackets. Please see examples below.
• If there are fewer than 4 authors, all of them should be mentioned in the bibliographic description. If there are more than 4 authors, only the first 3 should be mentioned, and the rest should be indicated as et al.
• If only editors of a book are mentioned, the editors’ names should be followed by “eds.” or “ed.” in English.
• There should be no commas between authors’ last names and their initials and no full stops after the initials.
• Bibliographic descriptions of journal articles should state the date of publication, volume and issue of the journal, and page numbers.
• The last page number should specify only the range that changes, e.g. 482–6 (instead of 482–486) or 359–63 (instead of 359–363).
• References should include DOIs or EDNs.
• The authors should not use PMC/Medline identifiers.

Formatting examples for references

Moiseev SV, Kuz’mina NE, Severinova EYu, Bunyatyan ND, Evteev VA. NMR spectroscopy study of the effect of the molecular mass of hypromellose phthalate on its solubility. Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. Regulatory Research and Medicine Evaluation. 2023;13(3):385–93 (In Russ.).
https://doi.org/10.30895/1991-2919-2023-541

Pecoraro C, Fioretti T, Perruno A, Klain A, Cioffi D, Ambrosio A, et al. De novo large deletions in the PHEX gene caused X-linked hypophosphataemic rickets in two Italian female infants successfully treated with burosumab. Diagnostics (Basel). 2023;13(15):2552.
https://doi.org/10.3390/diagnostics13152552 

Preprints:

The journal allows citing preprints. Citing a preprint is similar to citing a foreign article, but the authors should state the date the preprint was posted on the preprint server and note in square brackets that they are citing a preprint. At the stage of galley proof approval, the authors should check on the preprint server whether the article based on the preprint has been published and update the citation accordingly.

Heitmann S, Vandenberg JI, Hill AP. Assessing drug safety by identifying the axis of arrhythmia in cardiomyocyte electrophysiology [Preprint]. Posted 19.04.2023. bioRxiv. 537441.
https://doi.org/10.1101/2023.04.19.537441

Johnson G, Hill-Smith I, Bakhai C, eds. The minor illness manual. 6th ed. New York: CRC Press; 2024.

Chapters of a monograph or a collected book:

Maslova OV, Sen’ko OV, Stepanov NA, Efremenko EN. Biocatalytic synthesis of organic acids and plastics based on them. In: Varfolomeev SD, ed. Chemistry of biomass: biofuels and bioplastic. Moscow: Nauchny mir; 2017. P. 621–51 (In Russ.).

Indication of the name of the editor or compiler:

Merkulov VA, ed. Guidelines for the biomedical examination of biomedical cell products. Moscow: Melga; 2023 (In Russ.).

Scientific research in medicine and pharmacology. Conference proceedings of the international scientific-practical conference. Saratov; 2018 (In Russ.).

28th European meeting on hypertension and cardiovascular protection. Barcelona; 2018.

Patent specifications:

Kornilova OG, Krivykh MA, Voropaev AA, Khusnatdinova приEA. Standard sample of the content of the prekallikrein activator in human blood products. Patent of the Russian Federation No. 2756159; 2021 (In Russ.).
EDN: WSWQGN

X. Footnotes

• References to non-indexed sources (summaries of theses, theses, educational and instructional materials, laws and regulations (including pharmacopoeial monographs), state standards, guidelines and recommendations¹, information from websites², statistical documentation, scientific and technical documentation (including research and development reports) should be made as footnotes.
• Such references should be made using the MS Word tool “References” → “Insert Footnote” (Arabic numerals).
• For laws and regulations, as well as for guidelines and recommendations, the footnote should include the name of the document and its bibliographic description. 
• References to regulatory documents should include up-to-date information. 
• In addition to references to non-indexed sources, footnotes may also include the authors’ comments on some parts of the text. 
• Footnotes should be provided in the original language of the source and should not be translated.

• Datasets published in peer-reviewed journals are cited as articles in the references.

• The preprint must contain the date of posting on the server, as well as a note in square brackets that it is a preprint.

• For preprints, at the stage of approval of the layout, the authors should check on the preprint server whether an article has been published based on it, and make the correct replacement.

Other requirements

• If a manuscript contains the full official name of a document, information database, or another source, which allows for unambiguous identification of the source (for example, “the article analyses the provisions of Federal Law of the Russian Federation No. 61-FZ On Circulation of Medicines of April 12, 2010), the authors need not include information about this source in footnotes, because the information provided in the text is sufficient.
• For materials posted on the Internet and having no official bibliographic description, the footnotes should include the URL the page where the document is located.
• If the name of an official web site (of an organisation, database, register, etc.) is given in the text, the footnote may include only its URL (e.g. “according to the State Register of Medicinal Products”³).
• If the bibliographic description, including the document number, allows for unambiguous identification of a document, the web address of the document should not be included.
• Footnotes are numbered sequentially; each footnote has its own unique number.
• When a source is mentioned again in the text, it is assigned a new sequential number. In other words, one and the same source may appear in footnotes as many times as needed, and be assigned different numbers (e.g. 1, 6, and 8).
• If the information in a footnote repeats the information in the previous footnote, the authors may replace the full name of the source with "Ibid".
• Example: the text cites a source, and the next reference is to the same source (the full name of the source need not be repeated). In other cases, the authors should give the full name of the source again.
• Preprints⁴ and datasets⁵ are cited in footnotes.
• One footnote may include references to several sources.

Examples of footnotes

  ¹ ICH S6(R1) Preclinical safety evaluation of biotechnology-derived pharmaceuticals. ICH; 2011.
    Guideline on process validation for finished products – information and data to be provided in regulatory submissions. EMA/CHMP/CVMP/QWP/BWP/70278/2012-Rev1,Corr.1. EMA; 2016.

   ² Efficacy and tolerance of naked DNA vaccine in patients with chronic B hepatitis (VAC-ADN). https://clinicaltrials.gov/ct2/show/NCT00536627

   ³ Weight-of-Evidence Assessments: Unpacking New Guidance on Carcinogenicity Testing. February 1, 2023. https://premierconsulting.com/resources/blog/weight-of-evidence-assessments-unpacking-new-guidance-on-carcinogenicity-testing/
    https://grls.rosminzdrav.ru

⁴ Heitmann S, Vandenberg JI, Hill AP. Assessing drug safety by identifying the axis of arrhythmia in cardiomyocyte electrophysiology [Preprint]. Posted 19.04.2023. bioRxiv. 537441. https://doi.org/10.1101/2023.04.19.537441

⁵ Andrei V. Ivanov (2025), “ADA Trastuzumab Additional Data”, Mendeley Data, V2, https://doi.org/10.17632/fvfp4htspn.2

XI. Additional information, ethical and other statements

Each block (if any) of this section should be provided in Russian and in English.

Funding

If a grant has been awarded, it is important to specify the official name of the awarding organisation and include the grant number.

Example:

Funding. The study reported in this publication is a result of publicly funded research project No. 026-00020-21-00 and was supported by the Scientific Centre for Expert Evaluation of Medicinal Products (R&D reporting No. 124022200503-4).

Authorship and authors’ contributions

The journal adheres to the criteria for authorship outlined by the International Committee of Medical Journal Editors (ICMJE). The authors are individuals who fulfil all 4 of the following criteria:

• substantial contributions to the conception or design of the work; acquisition, analysis, or interpretation of data for the work; AND
• drafting the work and/or revising it critically for important content; AND
• final approval of the version to be published; AND
• agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

The journal encourages the authors to acknowledge contributors who played any other role in the preparation of the article than those outlined by the ICMJE. There are no requirements for using any particular international system for this. If the authors acknowledge contributions according to the CRediT (Contributor Roles Taxonomy) classification, including 14 roles, its tentative translation into Russian is provided HERE. The corresponding author is responsible for the co-operation between all authors on contribution details.

Examples:

Authors’ contributions. All the authors confirm that they meet the ICMJE criteria for authorship. Moreover, Petr P. Petrov performed additional statistical processing and visualisation of the obtained results.

Authors’ contributions. All the authors confirm that they meet the ICMJE criteria for authorship. The most significant contributions were as follows. Elena I. Ivanova conceptualised the study, developed the research methodology, and worked with the software. Petr P. Petrov curated the data and drafted the manuscript. Ivan P. Sidorov worked on the visualisation and conducted the study. Oksana P. Fedorova supervised the study. Igor I. Timonov provided the software and validated the data. Olga I. Egorova edited the manuscript.

Acknowledgements

• The authors may acknowledge individuals who contributed to the work but can not be considered authors according to the ICMJE criteria.
• The authors may also acknowledge organisations that supported them (e.g. by providing premises, materials, reagents, animals for the study, access to patients, etc.).
• It is important to specify names, companies, and organisations and refrain from acknowledging irrelevant and unspecific contributions (e.g. expressing gratitude to some anonymous journal reviewers).
• It is important to include the exact name of the organisation (and the country).
• When mentioning someone in acknowledgements, the authors should ask for permission to mention them. The authors will deal with all claims against the journal from third parties regarding unlawful mentions by the authors.

Example:

Acknowledgments. The authors express their gratitude to the staff of the departments that recruited patients and personally to the heads of these departments of City Clinical Hospital No. X, I.I. Ivanov, Dr. Sci. (Med.), P.P. Petrov, and S.S. Sidorov, Dr. Sci. (Med.).

Disclosure of potential conflicts of interest

This section should disclose any potential or actual conflicts of interest the authors may have. Any affiliations, financial relationships, financial or industry interests in the manuscript in whole or in part, including employment and other commitments, that could lead to deliberate concealment, misrepresentation, or misinterpretation of data are considered conflicts of interest and should be clearly declared as such. Nevertheless, conflicts of interest do not preclude publication. The journal requires disclosing potential conflicts of interest using the standard 13-item ICMJE Disclosure Form for Potential Conflicts of Interest. Based on the completed forms, the authors should generate the final disclosure statement. If none of the authors have a potential conflict of interest, they should still include a statement to that effect.

Example:

Disclosure. P.P. Petrov has been a member of the Editorial Board of Safety and Risk of Pharmacotherapy since 2021. I.I. Ivanov is the copyright holder and developer of the literature monitoring automation software EV®. However, this does not influence their view and interpretation of the facts and provisions discussed in this article. The other authors declare no conflict of interest.

Ethics approval

The full name of the ethics committee and details of the approval document (number and date) should be given for interventional studies. Please omit this section in articles on other studies.

Examples:

Ethics approval. According to the authors, the analysis was based on previously published anonymised data, and the study did not involve direct participation of human subjects. Hence, this study is exempt from ethics approval.

Ethics approval. The protocol of this observational clinical study was approved by the local ethics committee of the City Clinical Hospital No. X, Moscow Department of Healthcare (meeting minutes No. 29 of 21 October 2024).

Consent for publication

• This section is included only when it is applicable or when the article is a case report.
• If a clinical observation article does not require consent, this section should state “Not required”.
• The section and consent for publication are required if the manuscript contains data that provide for patient identification (e.g. medical history and photographs).
• Only in exceptional cases where no legal representatives can be found and the case is essential to medical practice, it may be published without consent, but the authors should clearly explain the lack of consent and indicate that every effort has been made to obtain it.
• A patient’s consent usually states that personal data will be anonymised, which should be done in the manuscript (e.g. by partly closing the patient’s face).
• It is not necessary to provide consent forms to the journal.
• You may find the recommended consent form here.

Example:

Consent for publication. The patient gave informed consent for processing of his personal data, as well as for anonymised publication of his medical information and photographs.

Data access and algorithmic transparency statement

The journal does not require, but encourages, the authors to include this section in their manuscripts, in accordance with its Research Data Sharing and Reproducibility policy.

The journal recommends using the following template for making a statement about providing access to source data.

Об авторах / Authors 

• This section should include the authors’ full names, academic degrees, titles, and ORCIDs (as http://orcid.org/0000-0000h0000) or other IDs in scientometric databases.
• The journal prohibits including personal information (e.g. a personal e-mail) in this section.
• In English, the authors’ names should be as follows: first name, middle initial, and last name (Ivan I. Ivanov).

XII. Recommended resources for manuscript preparation

Original article template
Case report template
Review template

Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals (Updated January 2025)

Section revision date: 18.07.2025

Submission Preparation Checklist

As part of the submission process, authors are required to check off their submission's compliance with all of the following items, and submissions may be returned to authors that do not adhere to these guidelines.

1. Manuscripts are accepted if they have not been published or submitted for publication elsewhere (or this fact is explained in the Commentaries for the editor).

2. The materials have to be submitted in the OpenOffice, Microsoft Word, RTF, or World Perfect format.

3. Internet links are provided as a complete URL, wherever possible.

4. Manuscript text should comply with the Author Guidelines.      

5. The article does not include the materials prohibited for publication, according to the current regulatory documents.

6. All the authors confirm that they meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship.

7. All the authors give their consent for processing and dissemination of their personal data according to Art. 6, Russian Federal Law No. 152-FZ of 27 July 2006 “On Personal Data” (including surname, name, patronymic, academic title and status, affiliation, and job/ study address) in order to publish the submitted article in the Journal.

Copyright Notice

Authors who have their articles published in this journal agree to the following terms:

1. The authors retain copyright for their work and grant the journal with the right of first publication under Creative Commons Attribution License that allows others to pass on the work provided they include references to the authors and the original publication.
2. The authors may post preprints and postprints and study data of their articles in institutional or public repositories in line with the journal’s Preprint and Postprint Deposition policy.

Privacy Statement

Specified when registering the names and addresses will be used solely for technical purposes of a contact with the Author or reviewers (editors) when preparing the article for publication. Private data will not be shared with other individuals and organizations.